logo conference-reports

Kongresszus figyelő

Educational funding by logo MSD Oncology

ASCO-GI 2019—NACT tops upfront surgery for PDAC in phase 2/3 trial

Gemcitabine plus S-1 extends OS in Japanese randomized study.